Last edition
News about
Zydus Wellness appoints Dr. Shyam Ramakrishnan as Chief Scientific Officer
Zydus Wellness has appointed Dr. Shyam Ramakrishnan as Chief Scientific Officer (CSO) to lead scientific strategy, drive innovation, and strengthen research in nutrition, health, and wellness.
Samsung Bioepis Relaunches Byooviz in US Through Commercial Partnership with Harrow
Samsung Bioepis has relaunched its ophthalmology biosimilar Byooviz in the US through its partnership with Harrow, expanding access to a lower-cost treatment option for patients with retinal diseases, including wet age-related macular degeneration.
BeOne Medicines Reports Positive Phase 3 Results for Brukinsa in First-Line Mantle Cell Lymphoma
BeOne Medicines has reported positive Phase 3 results from the MANGROVE trial, showing that Brukinsa combined with rituximab significantly improves progression-free survival in previously untreated mantle cell lymphoma.
Galderma has received a Complete Response Letter from the US FDA for its RelabotulinumtoxinA Biologics License Application, with observations limited to manufacturing processes and analytical methods.
Glenmark Pharma Receives Six Procedural Observations Following US FDA Inspection of Goa Facility
Glenmark Pharmaceuticals has received six procedural observations in a Form 483 following a US FDA GMP inspection of its Goa manufacturing facility. The company said there were no data integrity or repeat observations and expects no impact on the supply of its commercial products while it works with the regulator to address the findings.
Mankind Pharma Partners with Denovo Sciences to Accelerate AI-Driven Drug Discovery
The collaboration between Mankind Pharma and Denovo Sciences launches AI-powered drug discovery to accelerate research timelines and improve lead candidate quality.
Insilico Medicine and Takeda Collaborate on AI Drug Discovery
Takeda and Insilico Medicine are collaborating to advance Artificial Intelligence (AI)-powered drug discovery, leveraging the Pharma.AI platform to accelerate the development of therapeutics.
Roche's Divarasib Outperforms KRAS G12C Inhibitors in Phase 3 NSCLC Trial
Roche’s divarasib demonstrated superior Progression-Free Survival over approved KRAS G12C inhibitors in the phase 3 Krascendo-1 trial for previously treated advanced Non-Small Cell Lung Cancer (NSCLC).
Health Ministry Seeks Comments on Draft National Pharmacy Commission Bill 2026
The Union Health Ministry has released the revised Draft National Pharmacy Commission Bill, 2026 for public consultation, seeking stakeholder feedback.
WuXi Biologics Receives Brazil GMP Certification for Cancer Therapy Manufacturing
WuXi Biologics has received Brazil ANVISA GMP certification with zero inspection findings, enabling global commercial manufacturing of its innovative cancer immunotherapy.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy